Competitive Generic Therapies: Off-Patent Drugs With 1-4 Sources
✉ Email this page to a colleague
This table lists drugs which, despite having no patents or regulatory protections, have a limited number of active sources.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Strength |
|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 202912-001 | Dec 5, 2013 | RX | No | Yes | EQ 300MG BASE;150MG;300MG | |
| Bionpharma | ACAMPROSATE CALCIUM | acamprosate calcium | TABLET, DELAYED RELEASE;ORAL | 219904-001 | Sep 18, 2025 | AB | RX | No | No | 333MG |
| Glenmark Pharms Ltd | ACAMPROSATE CALCIUM | acamprosate calcium | TABLET, DELAYED RELEASE;ORAL | 202229-001 | Jul 16, 2013 | AB | RX | No | No | 333MG |
| Mylan | ACAMPROSATE CALCIUM | acamprosate calcium | TABLET, DELAYED RELEASE;ORAL | 200142-001 | Mar 11, 2014 | AB | RX | No | No | 333MG |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Strength |
